


## JAK-IN-26

<b>Cat. No.:</b>	HY-153701		
<b>CAS No.:</b>	2417134-93-9		
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>24</sub> N <sub>6</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	420.46		
<b>Target:</b>	JAK		
<b>Pathway:</b>	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (237.83 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	1 mM	2.3783 mL	11.8917 mL	23.7835 mL
	5 mM	0.4757 mL	2.3783 mL	4.7567 mL
	10 mM	0.2378 mL	1.1892 mL	2.3783 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.95 mM); Clear solution; Need ultrasonic  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.95 mM); Clear solution; Need ultrasonic			

### BIOLOGICAL ACTIVITY

<b>Description</b>	JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 inhibits IFN- $\alpha$ 2B-induced phosphorylation of STAT3 in Jurkat cells (IC <sub>50</sub> =17.2 nM) <sup>[1]</sup> .
--------------------	---

### REFERENCES

[1]. Zhou M, et al. Pyridine derivatives as TYK2 kinase inhibitors and preparation thereof. China, CN113563309 A 2021-10-29.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA